Alder BioPharmaceuticals, Inc. (ALDR) financial statements (2020 and earlier)

Company profile

Business Address 11804 NORTH CREEK PARKWAY SOUTH
BOTHELL, WA 98011
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments409475407452309331276
Cash and cash equivalents88126889411620277
Short-term investments321349320358193129199
Restricted cash and investments31245853 
Other undisclosed current assets114778711
Total current assets:452502420467321341287
Noncurrent Assets
Property, plant and equipment6665556
Long-term investments and receivables   222182460
Long-term investments   222182460
Restricted cash and investments   35810
Other noncurrent assets0000000
Other undisclosed noncurrent assets45     
Total noncurrent assets:111163022725916
TOTAL ASSETS:463513426497548599303
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities50592830292623
Accounts payable81591616137
Accrued liabilities42431913141216
Interest and dividends payable 1 1 1 
Deferred rent credit  000 
Deferred revenue and credits00
Other undisclosed current liabilities11     
Total current liabilities:51602830302623
Noncurrent Liabilities
Long-term debt and lease obligation188185182179176173 
Long-term debt, excluding current maturities188185182179176173 
Liabilities, other than long-term debt  11000
Deferred revenue and credits00
Deferred rent credit  110 
Other undisclosed noncurrent liabilities77222  
Total noncurrent liabilities:1951921841811781740
Total liabilities:24625221321220819924
Stockholders' equity
Stockholders' equity attributable to parent110157110184240302279
Common stock0000000
Additional paid in capital1,2511,2391,0751,0691,0641,058947
Accumulated other comprehensive loss(0)(0)(1)(2)(1)(1)(0)
Accumulated deficit(1,140)(1,082)(964)(884)(823)(755)(668)
Other undisclosed stockholders' equity10710410410110198 
Total stockholders' equity:217261214285341400279
TOTAL LIABILITIES AND EQUITY:463513426497548599303

Income statement (P&L) ($ in millions)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
Gross profit:      1
Operating expenses(56)(114)(77)(58)(65)(86)(56)
Operating loss:(56)(114)(77)(58)(65)(86)(55)
Nonoperating income (expense)(3)(4)(3)(2)(3)(1)1
Investment income, nonoperating2222321
Interest and debt expense(5)(5)(5)(5)(5)(3) 
Other undisclosed income from continuing operations before equity method investments, income taxes555553 
Loss from continuing operations before equity method investments, income taxes:(58)(118)(80)(61)(68)(87)(54)
Loss from equity method investments     (0)(0)
Net loss attributable to parent:(58)(118)(80)(61)(68)(87)(54)
Other undisclosed net loss available to common stockholders, basic(1)(1)(1)(1)(2)(31) 
Net loss available to common stockholders, diluted:(60)(119)(81)(62)(71)(118)(54)

Comprehensive Income ($ in millions)

6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
Net loss:(58)(118)(80)(61)(68)(87)(54)
Other comprehensive income (loss)010(0)(0)(1)(0)
Comprehensive loss, net of tax, attributable to parent:(58)(117)(80)(61)(69)(88)(54)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: